Eclevar MedTech is built on a rare combination of private investment from Medtech specialists and public recognition from the European clinical research community.
Eclevar MedTech is backed by Ballas Invest, an investment firm whose Medtech and digital health portfolio includes leaders such as Wandercraft ($75M Series D) and Hexoskin.
Ballas Invest's commitment is rooted in the development of MILO, our AI-driven clinical trial platform, recognized as a disruptive solution for medical device clinical research.
"ECLEVAR is at the forefront of clinical trial innovation. With Milo, the company has provided a groundbreaking solution that transforms the way trials are conducted."
— Ballas Invest, Portfolio Coverage
Non-Dilutive Recognition
On February 2, 2026, in Amsterdam, Eclevar MedTech received the Platinum Award, ranking first among European CROs evaluated by the European CRO Federation (EUCROF) in partnership with the European Commission.
Recognized for the methodological rigor of our clinical studies aligned with the EU MDR.
Validation of the MILO architecture and its native compatibility with regulatory ecosystems.
Focus on inclusive, geographically diverse, and sustainable clinical investigations.
Backed by a specialist Medtech investor with a long-term portfolio approach, Eclevar is structured for sustainable operations.
When a Notified Body sees Eclevar on a clinical evaluation report, they see a CRO officially endorsed by EUCROF.
